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Objective. The purpose of this study was to examine how patient, physician, and situational factors are associated with the extent
to which providers educate patients about glaucoma and glaucoma medications, and which patient and provider characteristics
are associated with whether providers educate patients about glaucoma and glaucoma medications. Methods. Patients with
glaucoma who were newly prescribed or on glaucoma medications were recruited and a cross-sectional study was conducted at six
ophthalmology clinics. Patients’ visits were videotape recorded and patients were interviewed after visits. Generalized estimating
equations were used to analyze the data. Results. Two hundred and seventy-nine patients participated. Providers were significantly
more likely to educate patients about glaucoma and glaucoma medications if they were newly prescribed glaucoma medications.
Providers were significantly less likely to educate African American patients about glaucoma. Providers were significantly less likely
to educate patients of lower health literacy about glaucoma medications. Conclusion. Eye care providers did not always educate
patients about glaucoma or glaucoma medications. Practice Implications. Providers should consider educating more patients about
what glaucoma is and how it is treated so that glaucoma patients can better understand their disease. Even if a patient has already
been educated once, it is important to reinforce what has been taught before.
1. Introduction
Glaucoma is one of the leading causes of blindness and
visual disability. An estimated 1.5 million Americans suffer
from glaucoma while approximately 120,000 of them have
been blinded by the disease. Between 9 and 12% of all
blindness in the United States is attributed to glaucoma
[1]. The primary goal of glaucoma treatment is to reduce
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intraocular pressure [2, 3]. Consistently taking intraocular
pressure-lowering glaucoma medications can significantly
reduce the progression of glaucoma [4, 5].
Little is known about ophthalmologist-patient commu-
nication during glaucoma visits [6]. Prior work has linked
inconsistent glaucoma follow-up with unfamiliarity with the
duration of glaucoma treatment and lack of knowledge of the
permanency of glaucoma-induced vision loss [7]. In a prior
study, researchers found that, even though most patients
reported their ophthalmologist was their primary source
of information about glaucoma, 15% reported that their
ophthalmologist told them either “not much” or “nothing”
about glaucoma [8].
Similarly, little is known about what ophthalmologists
actually tell patients about glaucoma during visits. One prior
study interviewed patients about what their ophthalmologists
discussed during visits [6], but they did not videotape
the patients’ visits to examine actual communication. The
researchers found that when patients were asked “how much
of what you know about glaucoma did you hear first from
your doctor?” 32% responded “all that they know,” 30% said
“most of what they know,” 32% said “some but notmuch,” and
5.3% said “nothing.” We need to have a better understanding
of what actually transpires between an ophthalmologist and
a patient during an encounter. Videotapes offer an impartial
method of assessing what actually transpires.
To our knowledge, no prior study has used videotape
recordings to examine the doctor-patient communication
to assess the extent to which ophthalmologists provide
education about glaucomamedications during visits and how
this is associated with various patient characteristics. When
evaluating antidepressant therapy, two prior studies found
that providers were more likely to give patients information
if they were newly prescribed an antidepressant for the first
time versus already being on one [9, 10]. In one study,
physicians were most likely to give the following type of
information about antidepressants: purpose (27.5%), dose
(22.5%), supply (15%), which antidepressant to take (15%),
and timing (12.5%) [9].
Prior audiotaped examinations of the doctor interactions
with patients with asthma have found that providers edu-
cated families about medications during 61% of visits [11].
Providers educated their patients about medications most
often in the following areas: (a) frequency/timing of use
(37%), (b) strength/dose (32%), and (c) purpose (30%). They
provided education regarding side effects during only 7% of
encounters [11]. Research is needed to better understand in
what areas ophthalmologists provide education for patients
about glaucoma and glaucoma medications.
The theoretical rationale for this study is the ecologic
model of communication in medical consultations [12, 13].
This model hypothesizes that the way patients communicate
with physicians is influenced by personal, physician, and
contextual factors [12, 13]. Personal factors could be the
patient’s gender, race, age, and health literacy; [13] provider
factors could be age, gender, and race; and contextual or
situational factors could be whether the visit is a follow-up
or an initial visit [12, 13].
Therefore, the purpose of this study was to apply the
ecologic model of communication in medical consultations
[12, 13] to examine how patient (age, gender, race, literacy,
and years of education), physician (age, gender, and race), and
situational (whether glaucoma medications are prescribed
for the first time) factors are associated with (a) the extent
to which providers educate patients about glaucoma and
glaucoma medications and (b) which patient and provider
characteristics are associated with whether providers educate
patients about glaucoma and glaucoma medications.
2. Patients and Methods
2.1. Procedure. Cross-sectional study took place at six geo-
graphically distinct ophthalmology clinics located in the
United States. Two sites were private offices and four
were affiliated with academic ophthalmology departments.
Patients were enrolled between 2009 and 2012. Eligibility
criteria included having the ability to speak and read English,
having a diagnosis of glaucoma, and being at least 18 years
of age. At each site, clinic staff referred eligible patients to
research assistants who were based at the clinics. Written
patient and provider consent was obtained. Providers com-
pleted a short demographic questionnaire after providing
consent. The patient’s medical visit was videotape recorded.
Patients were interviewed immediately after their medical
visits. The study was approved by the University of North
Carolina Institutional ReviewBoard,was performed in accor-
dance with the tenants of the Treaty of Helsinki, and was
HIPAA compliant.
2.2. Measurement
2.2.1. Patient, Provider, and Situational/Contextual Measures.
Patient age was measured as a continuous variable. Self-
reported patient race was measured as a categorical variable
(White, African American, Asian, Native American, and
Hispanic) and then recoded into African American and
non-African American. The majority of the non-African
American patient sample wasWhite (91%). Gender was mea-
sured as a dichotomous variable. The number of glaucoma
medications a subject was taking was recorded.
Each subject received the rapid estimate of adult literacy
in medicine (REALM). This is a validated, rapid screening
instrument designed to identify patients who have difficulty
reading common medical and lay terms that are routinely
used in patient education materials [14]. We chose the
REALM because it has high face validity and high criterion
validity, it has been well received by patients, and it only takes
two to three minutes to administer and score [14]. Patient
scores on the REALM correspond to reading levels (score of
0–60 = eighth grade and below and 61–66 = ninth grade and
above).
Physician age was measured as a continuous variable and
physician gender was measured as a dichotomous variable.
Self-reported physician race was measured as a categorical
variable (White, African American, Asian, Native American,
and Hispanic). We also examined whether gender and racial
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concordance between the provider and the patient influenced
provider education, but it was not significantly associated
with provider education about glaucoma or glaucoma medi-
cations, so it was not included in our analyses.The situational
factor we measured was whether the patient was prescribed
glaucoma medication for the first time during the medical
visit or was already on glaucoma medication prior to the
medical visit.
2.2.2. CommunicationMeasures. All medical visit videotapes
were transcribed into text verbatim with identifiers removed.
A detailed coding tool to assess communication was devel-
oped over a one-year period. The areas for education about
glaucoma and about glaucoma medications were developed
using prior literature and input from the pharmacists and
ophthalmologists on the study team [6–8]. The transcripts
were reviewed by a research assistant who met twice a month
with the investigators to develop and refine the coding rules.
Using the coding tool for transcribed medical vis-
its, coders recorded whether the provider educated the
patient in the following areas about glaucoma: (a) physical
changes with glaucoma and/or how tomanage these changes,
(b) emotional changes with glaucoma and/or how to manage
these changes, (c) diagnosis, (d) family history, (e) goals of
treatment, (f) how to problem solve, (g) intraocular pressure,
(h) likelihood of long-term therapy, (i) ways to manage
glaucoma other than with medications, and (j) prognosis.
Coders also recorded whether the provider educated
the patient in the following areas about glaucoma medica-
tions: (a) adherence and adherence strategies, (b) amount/
dose, (c) cost/insurance, (d) eyelid closure and nasolacrimal
occlusion when applying topical medications, (e) fear/
concerns/barriers, (f) frequency of use, (g) generic/brand,
(h) how well medication is working, (i) how to administer,
(j) side effects, (k) importance of use, (l) last time drops
were used, (m) length of use, (n) name of medication, (o)
nonglaucoma medications, (p) purpose, (q) supply, and (r)
which eye to instill the drops.
Two clinics had fellows examine some of the enrolled
patients while two other clinics had ophthalmic technicians
examine some of the enrolled patients. Informed consent
was obtained from these providers as well. If any one of
these healthcare providers, including the physician, educated
the patient, it was counted as education in the categories
discussed above.
Three research assistants coded 25 of the same transcripts
throughout the study period to assess inter-coder reliability
which was calculated using inter-rater correlations. Inter-
rater reliability was 0.76 for whether the physician provided
education about glaucoma and was 0.88 for whether the
physician provided education about glaucomamedications to
the patient.
2.2.3. Analysis. We set the a priori level of statistical signifi-
cance at 𝑃 < 0.05. First, we ran descriptive statistics. Second,
we examined the bivariate relationships between variables
using Pearson correlation coefficients, chi-square statistics,
and 𝑡-tests as appropriate. We then examined how whether






African American 99 (35.5)
Non-African American 179 (64.2)
Newly prescribed glaucoma medications at visit or
was on glaucoma medication before visit
Newly prescribed at visit 51 (18.3)
Was on glaucoma medications before visit 228 (81.7)
REALM
Eighth grade or lower 39 (14.0)
Ninth grade or higher 235 (84.2)
Age in years (mean ± SD) 65.8 ± 12.8
the patient was newly prescribed glaucoma medication on
the day of the visit was associated with the glaucoma and
glaucoma medication education areas using Pearson chi-
square.
We conducted generalized estimating equations (GEE)
to examine how patient’s age, gender, race, and health
literacy, whether the patient was newly prescribed glau-
coma medication on the day of the visit, physician age,
and physician gender, were associated with (a) whether
the physician provided any education about glaucoma and
(b) whether the physician provided any education about
glaucoma medications. Physician race could not be included
in the multivariable analysis because we only had one non-
White physician.
3. Results
Fifteen physicians who cared for glaucoma patients agreed to
participate in the study; one physician refused to participate
for a participation rate of 94%. Fourteen physicians were
White and one was African American. Ten physicians were
male (66.7%). Physician age ranged from26 to 66 years (mean
40.8 years, standard deviation 11.7 years).
Eighty-six percent of eligible patients participated in the
study. Table 1 presents the patient demographics. Forty-one
percent of the sample was male and 35.5% were African
American. Eighteen percent of patients were prescribed
glaucoma medications for the first time.
Providers educated patients about one or more glaucoma
medication areas during 74% of visits. Table 2 presents
the extent to which the providers educated the patients
about their medications in different areas. When patients
were newly prescribed glaucoma medications, the areas
that providers educated them about most often included
(a) side effects (80%), (b) purpose (45%), (c) adherence
and adherence strategies (39%), (d) frequency of use (37%),
(e) which eye to use the medicine in (33%), and (f) how to
administer the medicine (26%). Providers only educated 16%
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Table 2: Provider educates the patients about glaucoma medications by whether patients are prescribed glaucoma medications for the first
time or if they were on them before the visit (𝑁 = 279).
Areas provider educated the
patients about
Prescribed glaucoma medications for
first time during the visit (𝑁 = 51)
𝑁 (%)
Was on glaucoma medications




strategies 20 (39.2) 31 (13.6) 0.000
Amount/dose (number of drops) 8 (15.7) 8 (3.5) 0.001
Cost/insurance 6 (11.8) 17 (7.5) 0.309
Fear/concerns/barriers 4 (7.8) 7 (3.1) 0.123
Frequency of use 19 (37.3) 36 (15.8) 0.001
Generic/brand 4 (7.8) 21 (9.2) 0.760
How well medication is working 7 (13.7) 23 (10.1) 0.475
How to administer 13 (25.5) 27 (11.8) 0.014
Side effects 41 (80.4) 35 (15.4) 0.000
Importance of use 8 (15.7) 10 (4.4) 0.003
Last time used drops Not applicable 2 (0.9) 0.498
Length of use 0 (0) 0 (0) —
Name of medication 5 (9.8) 16 (7.0) 0.518
Nonglaucoma medications 5 (9.8) 18 (7.9) 0.681
Purpose 23 (45.1) 26 (11.4) 0.000
Supply 5 (9.8) 18 (7.9) 0.681
Which eye 17 (33.3) 13 (5.7) 0.000
Table 3: Provider educates the patients about glaucoma by whether patients are prescribed glaucoma medications for the first time or if they
were on them before the visit (𝑁 = 279).
Areas provider educated about
Prescribed glaucoma medications for
first time during the visit (𝑁 = 51)
𝑁 (%)
Was on glaucoma medications
before the visit (𝑁 = 228)
𝑁 (%)
𝑃
Physical changes that can occur with glaucoma
and/or how to manage these changes 27 (52.9) 60 (26.3) 0.000
Emotional changes that can occur with glaucoma
and/or how to manage these changes 0 (0) 1 (0.4) 0.633
Diagnosis 31 (60.8) 40 (17.5) 0.000
Family history 15 (29.4) 10 (4.4) 0.000
Goals of treatment 29 (56.9) 36 (15.8) 0.000
How to solve the problem 10 (19.6) 1 (0.4) 0.000
Intraocular pressure 29 (56.9) 106 (46.5) 0.219
Likelihood of long-term therapy 12 (23.5) 11 (4.8) 0.000
Management plan
(ways to manage glaucoma without medications) 8 (15.7) 29 (12.7) 0.605
Prognosis 16 (31.4) 59 (25.9) 0.478
of patients newly prescribed glaucoma medications on the
amount/dose to use, 16% about the importance of use, and
approximately 10% on the name of the medication.
As shown in Table 2, providers were significantly more
likely to educate patients who were newly prescribed glau-
coma medications than patients already on glaucoma medi-
cations in the following areas: (a) adherence and adherence
strategies, (b) amount/dose, (c) frequency of use, (d) how
to administer, (e) side effects, (f) importance of use, and
(g) purpose of the medications. For patients who continued
on glaucoma medications, providers were most likely to
provide education in the following areas: (a) frequency of
use (15.8%), (b) side effects (15.4%), and (c) adherence and
adherence strategies (13.6%).
Providers educated patients about one or more glaucoma
areas during 63% of visits. Table 3 presents the extent to
which providers educated the patients about glaucoma in
specific areas. When patients were started on glaucoma
medications for the first time, providers were most likely to
educate patients in the following areas: (a) diagnosis (60.8%),
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Table 4: Generalized estimating equation results predicting whether providers educate the patients about glaucoma and glaucoma
medications (𝑁 = 279).
Independent variables Education about glaucomaOR (95% CI) 𝑃
Education about glaucoma medications
OR (95% CI) 𝑃
Patient age 0.98 (0.96, 1.01) 0.377 1.01 (0.98, 1.04) 0.056
Patient gender: female 1.06 (0.64, 1.76) 0.235 1.12 (0.68, 1.84) 0.474
Patient race: African American 0.47 (0.34, 0.66) <0.001 1.67 (0.77, 3.62) 0.191
Newly prescribed glaucoma medications
versus already on glaucoma medications 5.24 (2.05, 13.4) 0.001 7.26 (3.61, 14.6) <0.001
REALM: reads at eighth grade level or less 0.93 (0.57, 1.51) 0.762 0.38 (0.18, 0.79) 0.009
Physician age 1.01 (0.97, 1.05) 0.742 1.04 (1.01, 1.07) 0.003
Physician gender-female 1.63 (0.70, 3.76) 0.257 2.24 (0.63, 7.9) 0.211
OR: odds ratio; 95% CI: 95% confidence interval.
(b) goals of treatment (56.9%), (c) intraocular pressure
(56.9%), and (d) physical changes that can occur with
glaucoma and/or how to manage these changes (52.9%).
Education about the emotional changes that can occur with
glaucoma and how to manage these changes only occurred
during one visit.
As shown in Table 3, providers were significantly more
likely to educate patients who were newly prescribed glau-
coma medications than patients already on glaucoma medi-
cations in the following areas: (a) physical changes that can
occur with glaucoma, (b) diagnosis, (c) goals of treatment,
(d) how to problem solve, and (e) likelihood of long-term
therapy. For patients who continued on glaucoma medi-
cation, providers were most likely to provide education in
the following areas: (a) intraocular pressure (46.5%), (b)
physical changes that can occur with glaucoma (26.3%), and
(c) prognosis (25.9%).
Table 4 presents the generalized estimating equation
results predicting whether providers educated patients about
glaucoma medications during visits. Older physicians were
significantlymore likely to provide education about glaucoma
medications than younger physicians (odds ratio = 1.04, 95%
confidence interval = 1.01, 1.07). Providers were significantly
less likely to provide glaucoma medication education to
patients with lower health literacy (odds ratio = 0.38, 95%
confidence interval = 0.18, 0.79). Providers were significantly
more likely to provide glaucoma medication education to
patients who were prescribed glaucoma medications for the
first time during the visit than to patients who were already
on glaucoma medications (odds ratio = 7.26, 95% confidence
interval = 3.6, 14.6).
Table 4 also presents the generalized estimating equation
results predicting whether providers educated patients about
glaucoma during visits. Providers were significantly less likely
to educate African American patients about glaucoma than
non-African American patients during visits (odds ratio =
0.47, 95% confidence interval = 0.34, 0.66). Providers were
significantly more likely to provide glaucoma education to
patients who were prescribed glaucoma medications for the
first time during the visit than to patients who were already
on glaucoma medications (odds ratio = 5.23, 95% confidence
interval = 2.1, 13.4).
4. Discussion and Conclusion
4.1. Discussion. Ophthalmologists educated their patients
about glaucoma during 74% of visits. Education about the
relevance of intraocular pressure occurred during only 57%
of visits where glaucomamedications were prescribed for the
first time and 47% of visits where the patient had already
been placed on a medication during a prior visit. Providers
should consider educating patients about the importance of
intraocular pressure reduction during every visit to assist in
reinforcing the importance of continued therapy.
Providers educated about the physical changes that occur
with glaucoma during 53% of visits, the likelihood of long-
term therapy during 24% of visits, and the goals of treatment
during 57% of the visits of the patients who were prescribed
glaucoma medications for the first time. Providers educated
continued users even less often in these areas. Providers
should consider educating more patients about these impor-
tant areas so that glaucoma patients better understand their
disease. Even if a patient has already been educated once, it is
important to reinforce what was taught before.
As predicted by the ecological model of communication
[12, 13], we found that a contextual factor (a patient being
prescribed a glaucoma medication for the first time versus
being a continued user) was significantly associated with
provider education about glaucoma. Specifically, patients
who were newly prescribed glaucoma medications during
the visit were significantly more likely to receive education
about glaucoma. Additionally, patient race was significantly
associated with provider education about glaucoma.
Providers were significantly less likely to educate African
American patients than non-African American patients
about glaucoma. This is an important finding because glau-
coma is the leading cause of irreversible blindness among
the African American population [15]. Also, prior work has
found that African Americans are less adherent to their
glaucomamedications thanWhite patients. [16–19] Providers
should make sure to educate patients equally from all racial
backgrounds. Other medical subspecialties have also found
differences in care given among races [20–25]. This is con-
sistent with other studies looking at racial disparities both in
causes of visual disabilities and testing [26].
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Providers educated about the emotional changes that
occur with glaucoma during only one visit. Having glaucoma
and having to use eye drops can be potentially stressful to
patients; thus, provider discussions of emotional changesmay
help patients feel more prepared to deal with this stress.
Providers should consider educating about the emotional
changes that occur with glaucoma and assessing whether
patients might have depressive symptoms or might be anx-
ious about having the disease or having to use eye drops.
Providers educated patients about their glaucoma medi-
cations during 63% of visits. As predicted by the ecological
model of communication [12, 13], we found that a contextual
factor (a patient being prescribed a glaucoma medication
for the first time versus being a continued user) was signif-
icantly associated with provider education about glaucoma
medications. Specifically, patients whowere newly prescribed
glaucoma medications during the visit were significantly
more likely to be educated about glaucoma medications.
Additionally, patient literacy was significantly associatedwith
provider education about glaucoma medications. Providers
were significantly less likely to educate patients who read
at an eighth grade level or below about their glaucoma
medications. This is an important finding because patients
with low health literacy are the ones who especially need
education about their glaucomamedications. Future research
should examine whether this is because providers believed
that patients with lower literacy would be less likely to
understand the information.
Providers educated the patients about the purpose of the
medication during 45% of visits, frequency of use during 37%
of visits, and how to administer the drops during 26% of
visits of patients who newly started on glaucomamedications
during the visit. Providers educated even fewer continued
users of glaucoma medications in these areas.These areas are
important when it comes to patients learning how to properly
use their glaucomamedications. Studies with asthma patients
have shown that patient medication technique deteriorates
with time. [27, 28] This could also be the case with instilling
eye drops. Thus, providers may want to periodically assess
patients’ eye drop technique.
Providers educated about the importance of adherence
to medications during only 39% of visits where medications
were prescribed for the first time and 14%of visits wheremed-
ications were continued. Providers should educate about the
importance of adherence to glaucomamedications during all
visits especially since nonadherence to glaucomamedications
may lead to worse clinical outcomes for glaucoma patients.
This study has several limitations. Providers and patients
both knew the visit was being recorded, but they did not know
the study hypotheses. Selection bias could be another limita-
tion since the ancillary staff did not track the characteristics
of the few patients who declined to speak with the research
assistant to learn more about the study. Additionally, our
coders counted the patient being educated about glaucoma
or glaucoma medications during visits regardless of whether
a physician, technician, or fellow provided it. A limitation
is that we coded the data this way so we cannot separate
out physician, technician, and fellow provision of education.
Also, since the examination roomswere periodically dimmed
during the medical visit, it was difficult to consistently
observe nonverbal communication between the healthcare
provider and the patient. Thus, we did not include nonverbal
communication in the analysis. Despite these limitations,
the study presents new information on the extent to which
providers educated patients about glaucoma and glaucoma
medications and highlights several areas where education can
be improved.
4.2. Conclusion. Eye care providers were less likely to educate
AfricanAmerican patients about glaucoma and theywere less
likely to educate patients of lower health literacy about glau-
comamedications. Providers were significantlymore likely to
educate patients about glaucoma and glaucoma medications
if they were newly prescribed glaucoma medications.
4.3. Practice Implications. Providers should consider educat-
ingmore patients aboutwhat glaucoma is andhow it is treated
so that glaucoma patients can better understand their disease.
Providers educated about the purpose of the medication,
frequency of use, and how to administer the drops during less
than 50% of visits of patients who newly started on glaucoma
medications during the visit. Providers educated even fewer
continued users of glaucoma medications in these areas.
These areas are important when it comes to patients learning
how to properly use their glaucoma medications. Even if a
patient has already been educated once, it is important to
reinforce what has been taught before.
Conflict of Interests
The authors have no conflict of interests to disclose.
Acknowledgments
This work was supported by Grant EY018400 from the
National Eye Institute (Betsy Sleath, PI) and by Grant UL
1RR02574 7 from the National Center of Research Resources,
NIH. NIH had no role in the design or conduct of this
research.
References
[1] “Glaucoma Research Foundation,” 2005, http://www.glaucoma
.org/.
[2] L. Pizzarello, A. Abiose, T. Ffytche et al., “VISION 2020:
the right to sight—a global initiative to eliminate avoidable
blindness,” Archives of Ophthalmology, vol. 122, no. 4, pp. 615–
620, 2004.
[3] M. O. Gordon, J. A. Beiser, J. D. Brandt et al., “The ocular hyper-
tension treatment study: baseline factors that predict the onset
of primary open-angle glaucoma,” Archives of Ophthalmology,
vol. 120, no. 6, pp. 714–720, 2002.
[4] E. J. Higginbotham, J. S. Schuman, I. Goldberg et al., “One-
year, randomized study comparing bimatoprost and timolol in
glaucoma and ocular hypertension,”Archives of Ophthalmology,
vol. 120, no. 10, pp. 1286–1293, 2002.
[5] C. B. Camras, A. Alm, P. Watson, and J. Stjernschantz, “Lat-
anoprost, a prostaglandin analog, for glaucoma therapy: efficacy
Journal of Ophthalmology 7
and safety after 1 year of treatment in 198 patients,”Ophthalmol-
ogy, vol. 103, no. 11, pp. 1916–1924, 1996.
[6] D. S. Friedman, S. R. Hahn, L. Gelb et al., “Doctor-patient com-
munication, health-related beliefs, and adherence in glaucoma.
Results from the glaucoma adherence and persistency study,”
Ophthalmology, vol. 115, no. 8, pp. 1320–1327.e3, 2008.
[7] Y. Murakami, B. W. Lee, M. Duncan et al., “Racial and ethnic
disparities in adherence to glaucoma follow-up visits in a county
hospital population,” Archives of Ophthalmology, vol. 129, no. 7,
pp. 872–878, 2011.
[8] L.W. Herndon, T. M. Brunner, and J. N. Rollins, “The glaucoma
research foundation patient survey: patient understanding of
glaucoma and its treatment,” American Journal of Ophthalmol-
ogy, vol. 141, no. 1, pp. S22–S27, 2006.
[9] B. Sleath, R. H. Rubin, and S. A. Huston, “Hispanic ethnicity,
physician-patient communication, and antidepressant adher-
ence,” Comprehensive Psychiatry, vol. 44, no. 3, pp. 198–204,
2003.
[10] B. Sleath, J. A. Tulsky, B. M. Peck, and J. Thorpe, “Provider-
patient communication about antidepressants among veterans
with mental health conditions,” The American Journal of Geri-
atric Pharmacotherapy, vol. 5, no. 1, pp. 9–17, 2007.
[11] B. Sleath, D. M. Carpenter, G. X. Ayala et al., “Provider
discussion, education, and question-asking about control med-
ications during pediatric asthma visits,” International Journal of
Pediatrics, vol. 2011, Article ID 212160, 7 pages, 2011.
[12] R. L. Street Jr., “Communication in medical encounters: an
ecological perspective,” inHandbook of Health Communication,
T. L. Thompson, A. Dorsey, K. Miller, and R. Parrott, Eds., pp.
63–89, Lawrence Erlbaum Associates, Mahwah, NJ, USA, 2003.
[13] R. L. Street Jr., H. S. Gordon, M. M. Ward, E. Krupat, and R.
L. Kravitz, “Patient participation in medical consultations: why
some patients aremore involved than others,”Medical Care, vol.
43, no. 10, pp. 960–969, 2005.
[14] T. C. Davis, S. W. Long, R. H. Jackson et al., “Rapid estimate of
adult literacy in medicine: a shortened screening instrument,”
Family Medicine, vol. 25, no. 6, pp. 391–395, 1993.
[15] N. Congdon, B. O’Colmain, C. C. Klaver et al., “Causes and
prevalence of visual impairment among adults in the United
States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477–485,
2004.
[16] B. Sleath, S. J. Blalock, D. Covert, A. C. Skinner, K.W.Muir, and
A. L. Robin, “Patient race, reported problems in using glaucoma
medications, and adherence,” ISRN Ophthalmology, vol. 2012,
Article ID 902819, 7 pages, 2012.
[17] B. L. Nordstrom, D. S. Friedman, E. Mozaffari, H. A. Quigley,
and A. M. Walker, “Persistence and adherence with topical
glaucoma therapy,” American Journal of Ophthalmology, vol.
140, no. 4, pp. 598.e1–598.e11, 2005.
[18] G. F. Schwartz, R. Platt, G. Reardon, and M. A. Mychaskiw,
“Accounting for restart rates in evaluating persistence with
ocular hypotensives,” Ophthalmology, vol. 114, no. 4, pp. 648–
652, 2007.
[19] D. S. Friedman, C. O. Okeke, H. D. Jampel et al., “Risk factors
for poor adherence to eyedrops in electronically monitored
patients with glaucoma,” Ophthalmology, vol. 116, no. 6, pp.
1097–1105, 2009.
[20] E. C. Schneider, P. D. Cleary, A.M. Zaslavsky, andA.M. Epstein,
“Racial disparity in influenza vaccination: does managed care
narrow the gap between African Americans and whites?” The
Journal of the AmericanMedical Association, vol. 286, no. 12, pp.
1455–1460, 2001.
[21] “Chronic disease prevention and health promotion,” Centers
for Disease Control and Prevention website, 2012, http://www
.cdc.gov/chronicdisease/resources/publications/AAG/chronic
.htm.
[22] S. Tavernise, “Whites account for under half of births in U.S.
New York Times,” 2012, http://www.nytimes.com/2012/05/17/.
[23] M.H. Lopez, “Latinos and education: explaining the attainment
gap,” Pew Research Center Publications website, 2009, http://
www.pewhispanic.org/2009/10/07/latinos-and-education-
explaining-the-attainment-gap/.
[24] D. Vlahov, K. T. Bond, K. C. Jones, and D. C. Ompad, “Factors
associated with differential uptake of seasonal influenza immu-
nizations among underserved communities during the 2009-
2010 influenza season,” Journal of CommunityHealth, vol. 37, no.
2, pp. 282–287, 2012.
[25] D. S. Friedman, S. K. West, B. Munoz et al., “Racial variations
in causes of vision loss in nursing homes: the Salisbury Eye
Evaluation in NursingHomeGroups (SEEING) study,”Archives
of Ophthalmology, vol. 122, no. 7, pp. 1019–1024, 2004.
[26] J. D. Stein, N. Talwar, A. M. Laverne, B. Nan, and P. R.
Lichter, “Racial disparities in the use of ancillary testing to
evaluate individuals with open-angle glaucoma,” Archives of
Ophthalmology, vol. 130, no. 12, pp. 1579–1588, 2012.
[27] D. Price and M. Duerden, “Inhalers: education and training
needs,” Current Therapeutics, vol. 43, no. 5, pp. 21–26, 28–29,
2002.
[28] G. K. Crompton, P. J. Barnes, M. Broeders et al., “The need
to improve inhalation technique in Europe: a report from the
Aerosol Drug Management Improvement Team,” Respiratory
Medicine, vol. 100, no. 9, pp. 1479–1494, 2006.
